CBD trial aims to stop psychosis before it starts
NCT ID NCT07434973
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether cannabidiol (CBD), a non-psychoactive cannabis compound, can reduce psychotic symptoms in 586 young people (ages 12-35) at high risk for psychosis. Participants take either CBD or a placebo daily for two years. The goal is to see if CBD can ease symptoms and prevent progression to full psychosis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL HIGH RISK FOR DEVELOPING PSYCHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Biobizkaia Health Research Institute (Asociación Instituto de Investigación Sanitaria)
Bilbao, Spain
-
Cambridgeshire and Peterborough NHS Foundation Trust
Cambridge, United Kingdom
-
Douglas Hospital Research Centre
Montreal, Canada
-
Foundation for Biomedical Research of the Gregorio Marañón Hospital (FIBHGM)
Madrid, Spain
-
IRCCS Santa Lucia Foundation
Roma, Italy
-
Institute of Psychiatry, Psychology & Neuroscience, King's College London
London, United Kingdom
-
Ludwig Maximilian University Hospital
München, Germany
-
MedUni Vienna, Department of Child and Adolescent Psychiatry
Vienna, Austria
-
National and Kapodistrian University of Athens
Athens, Greece
-
Oxford Health NHS Foundation Trust (OHFT)
Oxford, United Kingdom
-
Psychiatric University Hospital (PUK)
Zurich, Switzerland
-
Stichting Amsterdam UMC
Amsterdam, Netherlands
-
University Hospital Turku
Turku, Finland
-
University Medical Center Schleswig-Holstein
Lübeck, Germany
-
University of Bari Aldo Moro
Bari, Italy
-
University of Campania L. Vanvitelli
Naples, Italy
-
University of Cologne, Faculty of Medicine and University Hospital of Cologne
Cologne, Germany
-
University of Pavia
Pavia, Italy
-
Vivantes Network for Health GmbH
Berlin, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hope in action: peer support may curb suicide risk in youth facing psychosis
- Can eye games sharpen the mind in schizophrenia?
- New stepped care program aims to stop psychosis before it starts
- New french test could catch psychosis warning signs earlier in teens
- Mindfulness under the microscope: what it feels like for those at psychosis risk
- Can mindfulness stop psychosis before it starts?